![Douglas Thomson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Douglas Thomson
Direttore/Membro del Consiglio presso EnteroBiotix Ltd.
Profilo
Douglas Thomson is currently the Director & Investor Director at EnteroBiotix Ltd.
He previously worked as the Chief Executive Officer at Singvax Pte Ltd., Director-Business Development at Microscience Ltd., and Chief Operating Officer at Aquapharm Biodiscovery Ltd.
Posizioni attive di Douglas Thomson
Società | Posizione | Inizio |
---|---|---|
EnteroBiotix Ltd.
![]() EnteroBiotix Ltd. Medical SpecialtiesHealth Technology EnteroBiotix Ltd. develops novel microbiome modulating drugs which are composed of live microorganisms. It focuses on faecal microbiota transplantation which transfers bacteria from a healthy donor into a recipient having an infection caused by a bacterium called C.difficile. The company was founded by James Roger McIlroy in March 2017 and is headquartered in Aberdeen, the United Kingdom. | Direttore/Membro del Consiglio | 17/07/2023 |
Precedenti posizioni note di Douglas Thomson
Società | Posizione | Fine |
---|---|---|
Microscience Ltd.
![]() Microscience Ltd. Pharmaceuticals: MajorHealth Technology Microscience is an emerging vaccine company which is primarily involved in the discovery and development of innovative, rationally designed vaccines and immunotherapeutics for the prevention and treatment of disease in areas that the Company believes to represent a significant opportunity for new vaccines | Corporate Officer/Principal | - |
Singvax Pte Ltd.
![]() Singvax Pte Ltd. Medical SpecialtiesHealth Technology Singvax Pte Ltd. develops vaccines for infectious diseases. Its products include Chikungunya, Japanese Encephalitis, and Enterovirus 71. The company was founded in 2004 and is headquartered in Singapore | Presidente | - |
Aquapharm Biodiscovery Ltd.
![]() Aquapharm Biodiscovery Ltd. Pharmaceuticals: MajorHealth Technology Aquapharm Biodiscovery Ltd. discovers and develops drugs. It develops products for application across the pharmaceutical, personal care and nutrition sectors. The company offers antibiotics, inflammation & dermatology, oxidative stress, high value ingredients and anti-oxidant ingredients. Aquapharm Biodiscovery was founded by Kathryn Fraser and Andrew Mearns Spragg on April 11, 2000 and is headquartered in Edinburgh, GB. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Aquapharm Biodiscovery Ltd.
![]() Aquapharm Biodiscovery Ltd. Pharmaceuticals: MajorHealth Technology Aquapharm Biodiscovery Ltd. discovers and develops drugs. It develops products for application across the pharmaceutical, personal care and nutrition sectors. The company offers antibiotics, inflammation & dermatology, oxidative stress, high value ingredients and anti-oxidant ingredients. Aquapharm Biodiscovery was founded by Kathryn Fraser and Andrew Mearns Spragg on April 11, 2000 and is headquartered in Edinburgh, GB. | Health Technology |
Microscience Ltd.
![]() Microscience Ltd. Pharmaceuticals: MajorHealth Technology Microscience is an emerging vaccine company which is primarily involved in the discovery and development of innovative, rationally designed vaccines and immunotherapeutics for the prevention and treatment of disease in areas that the Company believes to represent a significant opportunity for new vaccines | Health Technology |
Singvax Pte Ltd.
![]() Singvax Pte Ltd. Medical SpecialtiesHealth Technology Singvax Pte Ltd. develops vaccines for infectious diseases. Its products include Chikungunya, Japanese Encephalitis, and Enterovirus 71. The company was founded in 2004 and is headquartered in Singapore | Health Technology |
EnteroBiotix Ltd.
![]() EnteroBiotix Ltd. Medical SpecialtiesHealth Technology EnteroBiotix Ltd. develops novel microbiome modulating drugs which are composed of live microorganisms. It focuses on faecal microbiota transplantation which transfers bacteria from a healthy donor into a recipient having an infection caused by a bacterium called C.difficile. The company was founded by James Roger McIlroy in March 2017 and is headquartered in Aberdeen, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Douglas Thomson